Author

Jan Kowalski 1

1 JK Biostatistics AB

CLINICAL DISEASE ACTIVITY INFLUENCES THE THERAPEUTIC EFFICACY OF THE TOLL LIKE RECEPTOR-9 AGONIST COBITOLIMOD IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS

Raja Atreya, Laurent Peyrin-Biroulet, Walter Reinisch, Franco Scaldaferri, Charlotte Admyre, Thomas Knittel, Jan Kowalski, Markus F. Neurath, Christopher John Hawkey

CLINICAL EFFICACY OF THE TOLL LIKE RECEPTOR-9 AGONIST COBITOLIMOD IN ANTI-TNF-ANTIBODY TREATED AND NAIVE PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS

Raja Atreya, Walter Reinisch, Laurent Peyrin-Biroulet, Franco Scaldaferri, Charlotte Admyre, Thomas Knittel, Jan Kowalski, Christopher John Hawkey

COBITOLIMOD FOR MODERATE-TO-SEVERE LEFT-SIDED ULCERATIVE COLITIS (CONDUCT): A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL

Raja Atreya, Laurent Peyrin–Biroulet, Andrii Klymenko, Monica Augustyn, Igor Bakulin, Dusan Slankamenac, Pal Miheller, Antonio Gasbarrini, Xavier Hebuterne, Karin Arnesson, Thomas Knittel, Jan Kowalski, Markus F. Neurath, William Sandborn, Walter Reinisch

HIGHLY SIGNIFICANT IMPROVEMENT IN DAI SUBSCORES BY LOCAL APPLICATION OF THE TOLL-LIKE RECEPTOR 9 AGONIST DIMS0150 IN MODERATELY SEVERE ULCERATIVE COLITIS PATIENTS

Thomas Knittel, Robert Löfberg, Jan Kowalski, Petra von Stein, Oliver von Stein

Item 1 - 4 / 4
1